Sichuan Kelun Biotech's shares slid sharply on Wednesday following a disclosure of a large pre-market placement priced at a notable discount to the previous closing level. The stock fell 8.2% to HK$471.8 after the company agreed to issue new H-shares before the opening bell on July 8.
Under the placement terms, the company will price approximately 5.84 million new H-shares at HK$470.20 each. That price represents a discount of about 8.5% compared with the prior session's close of HK$514. Global banks Goldman Sachs, Citigroup and JPMorgan are acting as joint bookrunners on the transaction.
The planned issuance is expected to generate net proceeds of roughly HK$2.72 billion. Management has specified that the funds will be allocated to drug research and development, ongoing clinical trials, manufacturing and commercialization activities, as well as general working capital. Company commentary in the disclosure framed the capital raise as a vote of confidence in its development pipeline - notably its flagship antibody-drug conjugate programs sac-TMT and trastuzumab botidotin.
Despite the stated strategic uses for the proceeds, the issuance comes with an estimated dilution of around 2.5% of existing share capital. That dilution, combined with the below-market placement price, triggered immediate selling by investors, driving the one-day share decline.
Market conditions offered limited support for the stock's price action. The Hang Seng index was rallying that session, led mainly by gains in technology names, but those broader market gains did not offset the pressure on Sichuan Kelun Biotech's shares.
The sequence of events highlights a capital-raising decision that balances funding needs for drug development and commercialization against near-term shareholder dilution and market reaction. The placement structure - executed pre-market and arranged by major international banks - produced a clear and rapid price response from investors.
Summary
Sichuan Kelun Biotech disclosed a pre-market placement of about 5.84 million H-shares at HK$470.20 each, a roughly 8.5% discount to the prior close, leading to an 8.2% drop in the stock to HK$471.8. The deal, arranged by Goldman Sachs, Citigroup and JPMorgan, is expected to raise about HK$2.72 billion to support R&D, trials, manufacturing and working capital, while diluting existing holders by about 2.5%.